Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Q-VANT Biosciences
About us
Q-SAP Technology
Process and Quality Approach for adjuvants
R&D Approach for Adjuvants
Team
News
Adjuvants
Saponin Adjuvants
Human
QS-21 XP
QS-21 GH
Veterinary
Security of supply
Importance of Supply Security and Affordability
The 100 Days Plan
Facilities
Biomass Supply
Vaccine formulation
Vaccine Formulation Guidance
Collaborations
Contact
Q-VANT Biosciences
About us
Q-SAP Technology
Process and Quality Approach for adjuvants
R&D Approach for Adjuvants
Team
News
Adjuvants
Saponin Adjuvants
Human
QS-21 XP
QS-21 GH
Veterinary
Security of supply
Importance of Supply Security and Affordability
The 100 Days Plan
Facilities
Biomass Supply
Vaccine formulation
Vaccine Formulation Guidance
Collaborations
Contact
Monthly Archives
November 2024
Q-VANT manufacturing facility is operational
News
Q-VANT manufacturing facility is operational
Search
Recent Posts
Q-VANT Biosciences and SPI Pharma Launch QS-21 GH to Expand Global Access to Advanced Vaccine Adjuvants
June 5, 2026
Q-VANT Biosciences Supports Next-Generation Oral Polio Vaccine
March 25, 2026
Q-VANT manufacturing facility is operational
November 26, 2024
Archives
June 2026
March 2026
November 2024
February 2024
January 2024
March 2022
January 2022
October 2021
